Last reviewed · How we verify
Anaplastic lymphoma kinase positive anaplastic large cell lymphoma — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Alecensa | alectinib | Hoffmann-La Roche | Kinase Inhibitor | ALK tyrosine kinase receptor | 2015-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Hoffmann-La Roche · 1 drug in Anaplastic lymphoma kinase positive anaplastic large cell lymphoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Anaplastic lymphoma kinase positive anaplastic large cell lymphoma:
- Anaplastic lymphoma kinase positive anaplastic large cell lymphoma treatment updates — RSS
- Anaplastic lymphoma kinase positive anaplastic large cell lymphoma treatment updates — Atom
- Anaplastic lymphoma kinase positive anaplastic large cell lymphoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Anaplastic lymphoma kinase positive anaplastic large cell lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anaplastic-lymphoma-kinase-positive-anaplastic-large-cell-lymphoma. Accessed 2026-06-11.
Related
- Anaplastic lymphoma kinase positive anaplastic large cell lymphoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing